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Abstract Box 
Antipsychotics are important in the treatment and recovery of people with psychosis 
but current evidence suggests that mental health nurses are not always conversant 
with the risks and benefits of these drugs. This inadequate knowledge has important 
ramifications for the provision of safe and effective medication management. This 
article outlines the utility and safety considerations associated with the different 
groups of antipsychotic drugs currently available in order that ………. 
 
Key Points Box 
The advent of antipsychotics have contributed to the revolutionalsation of mental 
health care but current antipsychotics are suboptimal 
First generation antipsychotics are effective in treating positive symptoms but not 
effective in treating cognitive or negative symptoms in psychosis. Further, they 
induce disabling motor side effects.  
Second generation antipsychotics are effective in trating positive symptoms and are 
modestly effective in treating negative and cognitive symptoms but they induce 
troubling metabolic side effects.  
Newer antipsychotics recently introduced have the potential to treat positive 
symptoms without inducing troubling motor or metabolic side effects. Further, drugs 
that target non dopamine systems currently under development offer hope of treating 






The risks and benefits of antipsychotics in the treatment of 
psychosis  
Introduction  
The central role of antipsychotics in the treatment of people with psychosis is now 
taken for granted by mental health professionals (Leucht et al. 2012) and service 
users also place a high importance in the use of medication to aid recovery  (Piat et 
al. 2009). Irrespective of these standpoints, the effectiveness of antipsychotics is a 
vexed issue for a number of reasons. One reason is that antipsychotics present a 
considerable risk in terms of their immediate and long-term adverse effects. 
Evidence suggests that patients taking these drugs are three times more likely to die 
suddenly from cardiac arrest or stroke than the general population (Straus et al. 
2004). Another reason relates to the widespread use of polypharmacy (Barnes and 
Paton 2011), which has significantly increased in recent years (Mojtabai and Olfson 
2010) despite evidence of the associated risks. For these reasons, the use of 
antipsychotics poses important challenges. At the same time, there is ample 
evidence suggesting that mental health nurses have inadequate working knowledge 
of pharmacology and this has frequently resulted in suboptimal care to patients 
(Latter et al. 2000; Kaas et al. 2000; Jordan et al. 1999; Skingsley et al. 2006; Page 
and McKinney 2007). Not surprisingly, this has resulted in nurses lacking in 
confidence when discussing treatment options with service users, carers and 
medical colleagues (Bressington et al. 2012).  
In response to the clear inadequacies in knowledge, the UK Nursing and Midwifery 
Council (NMC) have developed essential skills that nurses should demonstrate at 
the point of professional registration; the medication management essential skill 
cluster (ESC) number 36 states that:  “People can trust the newly registered 
graduate nurse to ensure safe and effective practice in medicines management 
through comprehensive knowledge of medicines their actions, risks and 
benefits”. In line with this guideline, this paper seeks to discuss the different groups 
of antipsychotics in terms of their effects upon symptoms, their common side effects 
and likely safety profiles.  
 
A little history  
The French surgeon, Henri Laborit, discovered antihistamine compounds (one of 
which was chlorpromazine), during his search for a preoperative sedative in the 
1940s. Chlorpromazine was observed to be dramatically effective in calming patients 
and its use spread to psychiatric clinics in the mid-1950s. The discovery that 
chlorpromazine dramatically reduced some psychotic symptoms stimulated the 
development of a range of antipsychotic drugs. These earlier drugs that are 
commonly referred to as conventional, classical or first generation antipsychotics 
(FGAs) are still in use today. Despite their effectiveness, these drugs induce very 
unpleasant motor side effects and this fuelled the development of the second 
generation antipsychotics (SGAs) which are also referred to as atypical 
antipsychotics. The therapeutic effects of all antipsychotics are mostly understood in 
terms of the dopamine hypothesis and this is summarised below.   
The dopamine hypothesis 
There are four known critical dopamine pathways in the brain; the mesolimbic, 
mesocortical, nigrostriatal and tuberoinfundibular pathways. At its most elementary 
exposition, the dopamine theory proposes that there is an imbalance of dopamine in 
the mesolimbic and mesocortical pathways. This imbalance causes abnormal 
neurotransmission that leads to symptom formation. Typically, in the mesolimbic 
pathway, there is excess dopamine causing synaptic “overload”. This ‘overload’ in 
turn causes an overstimulation of the post synaptic dopamine receptors, which 
manifests itself as positive symptoms such as delusions, hallucinations, thought 
disorder and bizarre behaviour. To prevent overstimulation and therefore symptom 
formation, antipsychotics work by blocking (or antagonising) post synaptic dopamine 
receptors. 
Negative symptoms are thought to arise through dopamine dysfunction in the 
mesocortical pathway that may involve insufficient stimulation or more likely, the 
deficit of dopamine (D1) receptors (bi-Dargham 2004). This under stimulation 
typically leads to the mood, negative and cognitive symptoms found in 
schizophrenia.  
Second and third generation antipsychotics are purported to be less likely to cause 
EPS and more effective at treating the cognitive, affective and negative symptoms 
because their mechanism of action is slightly different to FGAs. SGAs block 
serotonin receptors in addition to dopamine receptors, this blockade of the serotonin 
receptors in the nigrostriatal and mesocortical pathways has the effect of keeping 
dopamine in balance which reduces the likelihood of SGAs causing EPS and 
secondary negative symptoms.  
The potential benefits of antipsychotics  
With respect to FGAs, their therapeutic effect is generally associated with their ability 
to block mesolimbic dopamine receptors; however, when they block striatal 
dopamine receptors of by more than 80% this significantly increases the risk of 
extrapyramidal side effects (EPS) such as parkinsonism, dystonia, akathisia and 
tardive dyskinesia. Currently, there are at least 11 different classes of antipsychotic 
medications available and among them are FGAs group that include phenothiazines, 
butyrophenones and thioxanthenes. Though effective in treating positive symptoms 
of psychosis, these drugs are far from being optimal treatments (Miyamoto et al. 
2012). Between 30 and 60% of patients with acute psychotic symptoms completely 
fail or partially respond to these drugs and they are generally less effective against 
negative, mood and cognitive symptoms(Meltzer et al. 1998).  
Other limitations of FGAs are a relative lack of efficacy in relation to social 
functioning, quality of life, prevention of illness progression and improvement of long-
term outcomes. Therefore, the only group of patients in which FGAs are clearly 
indicated are those who prefer them because they have had an excellent response 
to them with minimal side effects (Sharif 1998). 
In response to the limited effectiveness and extensive side effects of FGAs, 
considerable effort has gone into developing a range of SGAs. These drugs include 
clozapine, olanzapine, quetiapine, risperidone and amisulpiride. The main advantage 
of SGAs is their reduced propensity to induce acute EPS and tardive dyskinesia. 
However, like FGAs, they also have their own distinct risks and benefits.  
There have been numerous double-blind trials comparing the efficacy and tolerability 
of SGAs with FGAs for acute and maintenance therapy in schizophrenia (Miyamoto 
et al. 2003; Buckley et al. 2001; Leucht et al. 2003), the results  suggest that SGAs 
are at least as effective as FGAs in alleviating positive symptoms of psychosis. 
However, there is ongoing debate as to whether SGAs are more efficacious overall 
than FGAs (Leucht et al, 2003). The conclusions from meta-analyses of eligible 
studies have not been entirely consistent. Geddes and colleagues reported similar 
efficacy when doses of haloperidol of 12 mg or less are used as a comparator to 
SGAs (Geddes et al, 2000). They further asserted that first generation antipsychotics 
are equally efficacious as a group but other investigators have concluded that some 
SGAs such as clozapine, olanzapine and risperidone are more efficacious than 
others, like sertindole, quetiapine and ziprasidone (Davis et al. 2003).  
Although there is tentative evidence that SGAs are more effective than FGAs in 
treating negative symptoms, there is continuing debate as to whether these apparent 
therapeutic effects are secondary to a reduction in EPS, a reduction in psychotic 
symptoms or a direct effect on primary negative symptoms (Remington and Kapur 
2000; Meltzer 1995). Examining the efficacy of antipsychotics on negative symptoms 
is fraught with problems because most clinical studies of SGAs do not distinguish 
between primary and secondary negative symptoms and generally involve very 
symptomatic patients undergoing treatment (Buchanan and Gold 1996).  
Though early studies of the effect of SGAs on cognitive symptoms were inconsistent 
(Keefe et al. 1999), relatively recent controlled studies have shown that in general, 
SGAs may be better for cognition when compared with FGAs (Stip et al. 2005). 
Specifically, studies seem to suggest that clozapine has a protective effect on 
attention while olanzapine has a positive effect on memory (Meltzer 2012b; Essali et 
al. 2009). With regard to efficacy for treatment-resistant schizophrenia, only 
clozapine is convincingly effective against psychotic symptoms in treatment-
refractory patients (Chakos et al. 2001; Essali et al. 2009). A Cochrane review of 52 
trials that compared clozapine with FGAs found clozapine to be superior to other 
antipsychotics on most outcome measures including symptom remission. 
Furthermore, patients seem more satisfied with clozapine treatment than with FGA 
treatment (Essali et al. 2009; Bressington et al. 2012a ). It is estimated that up to 
15% of patients with treatment resistant schizophrenia can experience an 
improvement of up to 60% within the first year of treatment with clozapine (Stahl 
2008).  
More recently, third generation antipsychotics (i.e. aripiprazole) with a unique 
mechanism of action and more favourable side effect profile are being used in 
practice. Generally referred to as partial agonists, these drugs have a unique 
receptor binding profile (Dhillon 2012). Aripiprazole partially blocks post synaptic 
dopamine receptors in situations of high dopamine concentrations (acute psychosis) 
thus, offering therapeutic benefits. Interestingly, the drug also occupies additional 
receptors and partially activates post synaptic dopamine receptors in situations 
where there is receptor under stimulation such as in the mesocortical region thereby 
improving negative, cognitive and mood symptom (Mailman and Murthy 2010).  
Aripiprazole is effective in treating positive and negative symptoms of schizophrenia 
with minimal EPS or metabolic side effects. A recent systematic review of short and 
long terms studies found that it is associated with improvements in positive, 
negative, cognitive, and affective symptoms of schizophrenia (Stip and Tourjman 
2010). As previously discussed, despite these potential benefits, all antipsychotics 
pose risks, some of which can be fatal.  
Potential risks of antipsychotics. 
Mental health professionals are undoubtedly responsible for sharing information 
about medication with service users, and monitoring the short and long term adverse 
effects of treatment. Clinicians also need to be mindful that the physical health state 
of people with severe mental illness is poor and the longer term use of antipsychotic 
medications can exacerbate this risk.  The occurrence of side effects can cause 
serious distress to patients, diminishing their quality of life, increasing carer burden 
and reducing adherence to medication (Keks 1996).   
In terms of adverse effects, the major difference between SGAs and FGAs is the 
lower incidence of EPS in SGAs. However, SGAs are often more sedating 
(especially olanzapine, clozapine and quetiapine), and there is robust evidence for 
their role in early metabolic problems, including weight gain, increased risk of Type-2 
diabetes and cardiovascular problems. Given the increased prevalence of 
cardiovascular disease in people with psychosis, it is paramount that service users 
are closely monitored for associated risk factors and made aware of the need to 
maintain a good diet and take regular exercise in order to go some way towards 
minimising the risks. Health promotion interventions should also be provided to early 
onset patients as antipsychotic related Type-2 diabetes is most likely to occur in 
younger adults (Saddichha et al. 2007).  
FGAs are well known to increase serum prolactin concentration in the usual clinical 
dose range leading to endocrine related side effects and sexual dysfunction (Meltzer 
1985). However, some SGAs (i.e. risperidone and amisulpiride) also increase 
prolactin serum levels and this can lead to hormonal related side effect effects such 
as menstrual abnormalities, galactorrhoea and sexual dysfunction. In the long term 
high prolactin levels can lead to reduced bone mineral density (Haddad and Wieck 
2004) and a potential increased risk of some cancers (Harvey et al. 2008). 
A relatively recent review of aripiprazole studies found that the most common 
adverse effects were nausea, insomnia and agitation but these effects were usually 
transient. This evidence suggests that aripiprazole is unlikely to be associated with 
clinically significant weight gain, dyslipidaemia, or increased prolactin levels. Overall, 
compared with placebo, aripiprazole has been reported to have a relatively low 
potential for inducing metabolic syndrome (Stip and Tourjman 2010).  
In addition to the more common and predictable adverse effects of antipsychotics, a 
number of relatively rare but serious risks are also associated with antipsychotic 
treatment. Most antipsychotics (perhaps excluding aripiprazole) can cause ECG 
changes, one of the most concerning of which is prolongation of the QTc interval. 
The data that relates to which antipsychotics are most likely to prolong QT is 
somewhat limited and therefore making risk prediction problematic. For example, 
haloperidol is likely to have a high effect, whilst quetiapine and chlorpromazine exert 
a moderate effect (Taylor 2009). As QTc prolongation is associated with sudden 
death in some individuals, ECG monitoring is vital and recommended by NICE 
guidelines for all patients prescribed antipsychotics.  
All antipsychotics can adversely affect the blood system. Such actions include 
increase (leucocytosis) or decrease (leucopenia) in the number of white blood cells, 
which usually occurs between 6 to 8 weeks after antipsychotic initiation. Except for 
clozapine, this condition is transient with the majority of antipsychotic medications. A 
life-threatening blood adverse effect (most usually associated with clozapine) is 
agranulocytosis; this condition is where the granulocyte producing ability of the bone 
marrow is severely diminished and this has a high mortality rate of 30%. The 
condition can occur within the first 3 months of antipsychotic treatment. Despite the 
severity of this condition and its association with clozapine, recent epidemiological 
studies suggest that clozapine has the lowest mortality rate of any antipsychotic 
drug, probably due to its very large effect in reducing the risk for suicide and 
frequency of blood monitoring(Meltzer 2012a) 
Neuroleptic malignant syndrome (NMS), like agranulocytosis, is a potentially fatal 
side effect of antipsychotic medication with an incidence rate of 0.02-3% and it can 
occur anytime during the course of antipsychotic treatment(Levenson 1985). It is 
typified by motor and behavioural symptoms that include muscular rigidity, dystonia, 
mutism and agitation. The autonomic system symptoms include hyperpyrexia, 
sweating, and increased pulse and blood pressure. Laboratory findings include 
increased white blood count, creatinine phosphokinase, liver enzymes, plasma 
myoglobin and myoglobinuria. The symptoms usually evolve over 72 hours, and the 
untreated symptoms can last for 10 to 14 days. The diagnosis is often missed during 
the early stages and withdrawal or agitation may be mistaken for increased 
psychosis. Men are affected more frequently than women and the mortality rate can 
reach 30% or higher when FGAs are involved. The cause of this serious condition is 
largely unknown. Multiple factors probably contribute to NMS, including dehydration, 
comorbid medical conditions and agitation (Mutsatsa 2011).  
All antipsychotics reduce the seizure threshold to some degree, and therefore 
seizures are a potential early complication of antipsychotic treatment. Among the 
first-generation antipsychotics (FGA) chlorpromazine appears to be associated with 
the greatest risk of seizures, whilst among the SGAs clozapine is thought to be most 
likely to cause convulsions (Lertxundi et al. 2012). The practical risk of seizures by 
all antipsychotics, however, is low, being 0.5 to 0.9% of all patients on antipsychotic 
treatment. Rapid upward titration of dosage is a risk factor, so is a history of 
seizures, CNS pathology and EEG abnormalities (Arana, 2000).  
Though evidence is tentative, all antipsychotics are associated with an increased risk 
of stroke. The risk might be higher in patients receiving SGAs than those receiving 
FGAs (Douglas and Smeeth 2008). The elderly with dementia seem to be at an 
increased risk of an associated stroke than people without dementia. It follows 
therefore that antipsychotics should be avoided when possible in people with 
dementia.  
Clearly, in spite of the importance of antipsychotics, areas of need remain and this 
has led to the recent introduction of newer drugs such as iloperidone, asenapine and 
lurasidone. Despite these medications being recently developed they are still classed 
as SGAs, this is because their mechanism of action does not involve the dopamine 
partial agonism seen in third generation drugs such as aripiprazole. All these newer 
medications are similar in terms of overall efficacy and low propensity for clinically 
significant weight gain or adverse changes in lipid profile. They however, differ from 
one another in terms of formulations, pharmacokinetics, dosing and metabolic 
adverse effect profiles (Bobo 2013). For example, asenapine is the first antipsychotic 
to be only administered sublingually, whereas iloperidone requires titration to 
minimize orthostatic hypotension. Asenapine and lurasidone are associated with 
dose-related akathisia, whereas iloperidone is not. Overall, the three newer 
antipsychotics seem to have a favourable metabolic side effect profile, therefore 
providing additional options for improved treatment in those with a propensity for 
developing metabolic syndromes.  
The future of antipsychotic treatment  
Because of the risk profile of current antipsychotics, the search for an ideal 
antipsychotic continues. The ideal antipsychotic should be efficacious in treating 
positive, negative or cognitive symptoms without compromising mental or physical 
well-being (Correll 2011).  
Contemporary research has focused on the critical involvement of glutamate 
receptors as potential targets for antipsychotic action, particularly in regards to 
disabling negative and cognitive symptoms that are poorly controlled by current 
antipsychotics. This is based on the refined glutamate hypothesis that postulates that 
behavioural and cognitive symptoms of schizophrenia appear to be caused by a 
dysregulation of glutamate neurotransmission. Frustratingly, the development of 
novel antipsychotics that bind directly to glutamate NMDA receptors has proven 
challenging.  Recently however, a number of potential drugs targeting the 
metabotropic glutamate receptor site (mGluRs) with the potential to alleviate 
cognitive and negative symptoms have been developed, some of which are at the 
clinical testing phase (Sendt et al. 2012). In addition, some non-glutamatergic 
potential antipsychotics have shown promise. These compounds are the non-
hallucinogenic cannabinoid cannabidiol (Hallak et al. 2011) as well as the selective 
muscarinic (M1/M4) receptor agonist xanomeline. However, further preclinical work 
is required to evaluate their suitability as viable antipsychotic treatment drugs. 
Conclusion  
Although the advent of FGAs and SGAs has significantly contributed to the 
revolutionalisation of mental health car, problems because of treatment persist. 
FGAs induce troubling motor side effects and have little or no effect in treating 
negative and cognitive symptoms that are common in schizophrenia. With respect 
SGAs, they are modestly effective in treating cognitive and negative symptoms but 
they give rise to metabolic side effects. Relatively recent antipsychotics such as 
asenapine are purported to be better at controlling psychotic symptoms without 
inducing motor or metabolic side effects. There is considerable hope that drugs that 
target the glutamate and non glutamate system currently under development, may 
offer considerable hope in treating positive, cognitive and negative symptoms of 
psychosis without inducing troubling side effects. Overall, very troubling or potentially 
fatal side effects underpin current antipsychotic treatment. In this regard, it is 
imperative that mental health nurses should underpin their practice by a 
comprehensive knowledge of antipsychotics their actions, risks and benefits as these 
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